# US 6,727,267 B2 · NS5B HVC polymerase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,267 B2
- Document ID: US6727267B2
- Status: Granted
- Kind: B2
- Application number: 09/828,270
- Filed: 2001-04-05
- Published: 2002-10-03
- Granted: 2004-04-27
- Earliest claimed: 2001-04-05
- Assignees: Tularik Inc.
- Inventors: Juan C. Jaen; Jay P. Powers
- Web page: https://patentgrep.com/patent/US6727267B2

## CPC

- C07D 277/20: having two or three double bonds between ring members or between ring members and non-ring members
- A61P 31/12: Antivirals
- C07D 207/48: Sulfur atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, compositions and methods are provided that are useful in the treatment and prevention of certain viral infections and associated diseases. In particular, the compounds of the invention inhibit the activity of a viral RNA polymerase. The subject methods are particularly useful in the treatment of diseases causes by hepatitis C virus infection.

## Claims

### Claim 1

A compound having the formula (VIIa):
wherein
Ar1 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
X is selected from —S—, —O—and —N(RO)—, wherein RO is H or lower alkyl;
Y is O or S; and
Z is O, S or N(R2d), wherein R2d is H or lower alkyl, or R2d and R1 may be joined to form an imidazole or benzimidazole group; and
R2 is a substituted or unsubstituted mono- or bi-heterocyclic group, a substituted or unsubstituted polycyclic ring, a substituted or unsubstituted alicyclic group having 5-8 carbon atoms, a substituted or unsubstituted phenyl group, a substituted or unsubstituted biphenyl group, a substituted or unsubstituted phenylether group, a substituted or unsubstituted cinnamenyl group, or a substituted or unsubstituted stilbenyl group.

### Claim 2

The compound of claim,1 wherein said compound is selected from the group consisting of

### Claim 3 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically or prophylactically effective amount of a compound of claim 1.

### Claim 4 (depends on 1)

A method for the treatment or prevention of a viral infection, comprising
administering to a subject suffering from or at risk for said viral infection an effective amount of a compound of claim 1.
